Berkeley, CA, August 2, 2021 – FlemingMartin is pleased to announce that Chinook Therapeutics (NASDAQ: KDNY), a company dedicated to discovering, developing, and commercializing precision medicines for kidney disease, has hired Frelon “Fre” Ngai as Senior Director of Financial Planning & Analysis. With more than 20 years of life sciences finance experience, Fre will steer the FP&A function and play a principal role in shaping this ascending company’s continued growth and evolution.
Fre joins Chinook Therapeutics after helping lead R&D Finance at Gilead Sciences, where he held responsibility for forecasting, budgeting, and decision support for the Development and Medical Affairs functions. Prior to Gilead, Fre earned consistent promotions to finance positions of increasing responsibility at Jazz Pharmaceuticals, Genentech, and Life Technologies. Fre received his MBA from the University of California, San Diego and was awarded a bachelor’s degree in Molecular & Cell Biology from the University of California, Berkeley.
Chinook Therapeutics (NASDAQ: KDNY) is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. To learn more, visit chinooktx.com
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs of companies to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. flemingmartin.com